FDA Taking “Risk-Based Approach” To Sequestration Cuts
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will try to manage $319 million in potential funding reductions in a way that minimizes negative effects on health and safety, FDA Commissioner Hamburg tells the Science Board, but significant layoffs seem unavoidable if sequestration is enacted.
You may also be interested in...
How Do You Solve A Problem Like Sequestration?
FDA and advocates wait for OMB to clarify how the estimated 7.8% budget cut should be implemented, if it is enacted. Former agency officials say it could lead to hiring freezes and program delays.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.